RecruitingPhase 4NCT06757764

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial


Sponsor

Asan Medical Center

Enrollment

2,340 participants

Start Date

Jul 10, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.


Eligibility

Min Age: 20 Years

Inclusion Criteria4

  • Age of 20 years or older
  • Acute ischemic stroke due to large artery atherosclerosis (both including Intra and extracranial atherosclerosis) which may be defined by a ischemic lesion confirmed at diffusion-weighted image and a corresponding significant stenosis (more than 50% of diameter reduction) proximal to the ischemic lesion confirmed by MR angiography or CT angiography.
  • Informed consent obtained within 72h from stroke onset
  • Acquisition of written informed consent prior to study entry

Exclusion Criteria11

  • Large infarction unable to start antiplatelet treatment
  • Combined with acute intracranial haemorrhage
  • With initial haemorrhagic transformation
  • Previous mRS higher than 2
  • Indicated for anticoagulation
  • Contraindication for aspirin, clopidogrel or cilostazol
  • Requirement of long term NSAID
  • Pre-planned for surgery
  • Unable to withdraw consent
  • Unavailable to participate based on judgement of the investigator
  • Participants of reproductive potential (PORP)/ Participants of childbearing potential (POCBP) who do not agree to practice methods of birth control or remain fully abstinent from sexual activity with the potential for conception.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAspirin

Aspirin 100mg qd (21days) * In case of stenting, aspirin will be added to cilostazol and clopidogrel until 90 days after stenting. * Route: per oral. IMP can be taken with or without food. * Frequency: once daily (qd)

DRUGClopidogrel

Clopidogrel 75mg qd (180days) * Route: per oral. IMP can be taken with or without food. * Frequency: once daily (qd)

DRUGCilostazol

Cilostazol SR 100mg x 2cap (180days) * Route: per oral. IMP can be taken with or without food. * Frequency: once daily (qd)

DRUGPlacebo

Placebo x 2cap (180days) * Route: per oral. IMP can be taken with or without food. * Frequency: once daily (qd)


Locations(24)

Asan Medical Center

Seoul, Songpa-gu, South Korea

Pusan National University Hospital

Busan, South Korea

Chungbuk National University Hospital

Cheongju-si, South Korea

Kyungpook National University Chilgok Hospital

Daegu, South Korea

Chungnam National University Hospital

Daejeon, South Korea

Eulji University Hospital

Daejeon, South Korea

Chonnam National University Hospital

Gwangju, South Korea

Seoul National University Bundang Hospital

Gyeonggi-do, South Korea

Hallym University Medical Center

Gyeonggi-do, South Korea

Hanyang University Guri Hospital

Gyeonggi-do, South Korea

Korea University Ansan Hospital

Gyeonggi-do, South Korea

Gachon University Gil Medical Center

Incheon, South Korea

Inha University Hospital

Incheon, South Korea

Jeju National University Hospital

Jeju City, South Korea

Jeonbuk National University Hospital

Jeonju, South Korea

Ewha Womans University Seoul Hospital

Seoul, South Korea

Hanyang University Seoul Hospital

Seoul, South Korea

Korea University Guro Hospital

Seoul, South Korea

Kyung Hee University Hospital at Gangdong

Seoul, South Korea

Kyung Hee University Hospital

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, South Korea

Yonsei University Health System, Gangnam Severance Hospital

Seoul, South Korea

Pusan National University Yangsan Hospital

Yangsan, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06757764


Related Trials